In a retrospective study of NSCLC patients with brain metastases, the addition of anti-PD-1 to whole brain radiotherapy (WBRT) showed better survival compared to WBRT alone (median OS, 27 versus 20 months) in patients with brain metastases (95). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.